9 March 2026 - Report will be subject of CTAF meeting in October 2026; draft scoping document open to public comment until 27 March 2026.

The ICER announced today that it will assess the comparative clinical effectiveness and value of tavapadon (AbbVie) for Parkinson’s disease.

Read ICER Announcement